News
Video
Author(s):
Dr. Shirish Gadgeel discusses recent EVOKE-2 trial results showing promising response rates with sacituzumab govitecan combined with pembrolizumab for metastatic non-small cell lung cancer.
China’s NMPA Gives Go Ahead to Toripalimab Plus Chemotherapy in First-Line ES-SCLC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
FDA Approval Sought for Subcutaneous Amivantamab in EGFR+ NSCLC
Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC
Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC
Frontline Acalabrutinib/BR Regimen Significantly Improves PFS in Mantle Cell Lymphoma
Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL
Linvoseltamab Elicits Deep, Durable Responses in R/R Multiple Myeloma
Prospective Analysis Highlights Patterns of Progression to Myelofibrosis Following Essential Thrombocythemia Diagnosis